In the context of pharmaceutical marketing, when we work with our clients to launch and support their products in the marketplace, we think about access in the following distinct ways...

The growing need for mental health services in the United States has become increasingly urgent...

With growing scrutiny of the role PBMs play in the pharmaceutical supply chain, we dive into the FTC’s recent administrative complaint...

Now that we're a bit removed from the COVID-19 crisis, let’s consider some key takeaways from a few relevant stakeholders...

Based on our own qualitative primary research conducted with payers, we have an idea on what is keeping them up at night.

There is a lot to accomplish during the post-launch period to ensure a product's success. Here are 6 key priorities to keep top of mind.

It’s not news that the United States has an obesity problem. However, newer medications are the first truly effective obesity treatments...

When informing a payer customer about a complicated new product, how do you know what will matter? And how do you get and keep them engaged?

One of the principal stories of the US healthcare industry over the past several years is one of consolidation...

The IRA reforms on prescription drug pricing and coverage is definitely on payers' radar. See what else our research uncovered ...

While Digital Therapeutics offer great promise and renewed hope to improve patient outcomes, they need to overcome several challenges...

Patient-centric communications encourage reaching individuals with the information that they need in a form that they can use. See how ...